602 related articles for article (PubMed ID: 27617860)
21. Progerin reduces LAP2α-telomere association in Hutchinson-Gilford progeria.
Chojnowski A; Ong PF; Wong ES; Lim JS; Mutalif RA; Navasankari R; Dutta B; Yang H; Liow YY; Sze SK; Boudier T; Wright GD; Colman A; Burke B; Stewart CL; Dreesen O
Elife; 2015 Aug; 4():. PubMed ID: 26312502
[TBL] [Abstract][Full Text] [Related]
22. A conserved splicing mechanism of the LMNA gene controls premature aging.
Lopez-Mejia IC; Vautrot V; De Toledo M; Behm-Ansmant I; Bourgeois CF; Navarro CL; Osorio FG; Freije JM; Stévenin J; De Sandre-Giovannoli A; Lopez-Otin C; Lévy N; Branlant C; Tazi J
Hum Mol Genet; 2011 Dec; 20(23):4540-55. PubMed ID: 21875900
[TBL] [Abstract][Full Text] [Related]
23. In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice.
Koblan LW; Erdos MR; Wilson C; Cabral WA; Levy JM; Xiong ZM; Tavarez UL; Davison LM; Gete YG; Mao X; Newby GA; Doherty SP; Narisu N; Sheng Q; Krilow C; Lin CY; Gordon LB; Cao K; Collins FS; Brown JD; Liu DR
Nature; 2021 Jan; 589(7843):608-614. PubMed ID: 33408413
[TBL] [Abstract][Full Text] [Related]
24. Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody.
McClintock D; Gordon LB; Djabali K
Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2154-9. PubMed ID: 16461887
[TBL] [Abstract][Full Text] [Related]
25. Rescue of heterochromatin organization in Hutchinson-Gilford progeria by drug treatment.
Columbaro M; Capanni C; Mattioli E; Novelli G; Parnaik VK; Squarzoni S; Maraldi NM; Lattanzi G
Cell Mol Life Sci; 2005 Nov; 62(22):2669-78. PubMed ID: 16261260
[TBL] [Abstract][Full Text] [Related]
26. MG132-induced progerin clearance is mediated by autophagy activation and splicing regulation.
Harhouri K; Navarro C; Depetris D; Mattei MG; Nissan X; Cau P; De Sandre-Giovannoli A; Lévy N
EMBO Mol Med; 2017 Sep; 9(9):1294-1313. PubMed ID: 28674081
[TBL] [Abstract][Full Text] [Related]
27. Emerging candidate treatment strategies for Hutchinson-Gilford progeria syndrome.
Strandgren C; Revêchon G; Sola-Carvajal A; Eriksson M
Biochem Soc Trans; 2017 Dec; 45(6):1279-1293. PubMed ID: 29127216
[TBL] [Abstract][Full Text] [Related]
28. Status of treatment strategies for Hutchinson-Gilford progeria syndrome with a focus on prelamin: A posttranslational modification.
Chen X; Yao H; Andrés V; Bergo MO; Kashif M
Basic Clin Pharmacol Toxicol; 2022 Oct; 131(4):217-223. PubMed ID: 35790078
[TBL] [Abstract][Full Text] [Related]
29. Dysregulated interactions between lamin A and SUN1 induce abnormalities in the nuclear envelope and endoplasmic reticulum in progeric laminopathies.
Chen ZJ; Wang WP; Chen YC; Wang JY; Lin WH; Tai LA; Liou GG; Yang CS; Chi YH
J Cell Sci; 2014 Apr; 127(Pt 8):1792-804. PubMed ID: 24522183
[TBL] [Abstract][Full Text] [Related]
30. Unique progerin C-terminal peptide ameliorates Hutchinson-Gilford progeria syndrome phenotype by rescuing BUBR1.
Zhang N; Hu Q; Sui T; Fu L; Zhang X; Wang Y; Zhu X; Huang B; Lu J; Li Z; Zhang Y
Nat Aging; 2023 Feb; 3(2):185-201. PubMed ID: 37118121
[TBL] [Abstract][Full Text] [Related]
31. Transgene silencing of the Hutchinson-Gilford progeria syndrome mutation results in a reversible bone phenotype, whereas resveratrol treatment does not show overall beneficial effects.
Strandgren C; Nasser HA; McKenna T; Koskela A; Tuukkanen J; Ohlsson C; Rozell B; Eriksson M
FASEB J; 2015 Aug; 29(8):3193-205. PubMed ID: 25877214
[TBL] [Abstract][Full Text] [Related]
32. Progerinin, an Inhibitor of Progerin, Alleviates Cardiac Abnormalities in a Model Mouse of Hutchinson-Gilford Progeria Syndrome.
Kang SM; Seo S; Song EJ; Kweon O; Jo AH; Park S; Woo TG; Kim BH; Oh GT; Park BJ
Cells; 2023 Apr; 12(9):. PubMed ID: 37174632
[TBL] [Abstract][Full Text] [Related]
33. All-trans retinoic acid and rapamycin normalize Hutchinson Gilford progeria fibroblast phenotype.
Pellegrini C; Columbaro M; Capanni C; D'Apice MR; Cavallo C; Murdocca M; Lattanzi G; Squarzoni S
Oncotarget; 2015 Oct; 6(30):29914-28. PubMed ID: 26359359
[TBL] [Abstract][Full Text] [Related]
34. Hutchinson-Gilford Progeria Syndrome: A premature aging disease caused by LMNA gene mutations.
Gonzalo S; Kreienkamp R; Askjaer P
Ageing Res Rev; 2017 Jan; 33():18-29. PubMed ID: 27374873
[TBL] [Abstract][Full Text] [Related]
35. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts.
Bikkul MU; Clements CS; Godwin LS; Goldberg MW; Kill IR; Bridger JM
Biogerontology; 2018 Dec; 19(6):579-602. PubMed ID: 29907918
[TBL] [Abstract][Full Text] [Related]
36. Plasma Progerin in Patients With Hutchinson-Gilford Progeria Syndrome: Immunoassay Development and Clinical Evaluation.
Gordon LB; Norris W; Hamren S; Goodson R; LeClair J; Massaro J; Lyass A; D'Agostino RB; Tuminelli K; Kieran MW; Kleinman ME
Circulation; 2023 Jun; 147(23):1734-1744. PubMed ID: 36919608
[TBL] [Abstract][Full Text] [Related]
37. An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome.
Harhouri K; Frankel D; Bartoli C; Roll P; De Sandre-Giovannoli A; Lévy N
Nucleus; 2018 Jan; 9(1):246-257. PubMed ID: 29619863
[TBL] [Abstract][Full Text] [Related]
38. Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome.
Scaffidi P; Misteli T
Nat Med; 2005 Apr; 11(4):440-5. PubMed ID: 15750600
[TBL] [Abstract][Full Text] [Related]
39. Modulation of LMNA splicing as a strategy to treat prelamin A diseases.
Lee JM; Nobumori C; Tu Y; Choi C; Yang SH; Jung HJ; Vickers TA; Rigo F; Bennett CF; Young SG; Fong LG
J Clin Invest; 2016 Apr; 126(4):1592-602. PubMed ID: 26999604
[TBL] [Abstract][Full Text] [Related]
40. Increased progerin expression associated with unusual LMNA mutations causes severe progeroid syndromes.
Moulson CL; Fong LG; Gardner JM; Farber EA; Go G; Passariello A; Grange DK; Young SG; Miner JH
Hum Mutat; 2007 Sep; 28(9):882-9. PubMed ID: 17469202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
